<DOC>
	<DOC>NCT01201343</DOC>
	<brief_summary>This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects. This is an open-label exploratory study with no change of therapeutic behavior but with standardized neuropsychologic follow-up.</brief_summary>
	<brief_title>Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients</brief_title>
	<detailed_description>This study is planned to evaluate emotional disorders during treatment by IFN beta in RRMS subjects. This is an open-label, prospective, interventional, multicentric study with no change of therapeutic behavior but with standardized neuropsychologic follow-up. Subjects will undergo 13 evaluations (categorical and dimensional evaluations), 3 evaluations will be performed before the treatment (Baseline, Day 7 and 15) and 10 evaluations after the treatment (Month 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24).</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male and female subjects aged â‰¥ 18 years Subjects with RRMS Subjects with at least 2 relapses in the past two years (with last relapse finished or finishing) Subjects with indication of IFN beta treatment determined by the investigator Other protocoldefined inclusion criteria may apply Subjects with secondary progressive multiple sclerosis (MS) without relapse Subjects with ongoing acute relapse Subjects already being treated with interferon Subjects with corticoid therapy for less than 15 days Subjects presenting acute major depression or treated with antidepressant therapy Subjects involved in another therapeutic study Subjects with any condition which could interfere with a good compliance of this study Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Multiple sclerosis, relapsing, remitting</keyword>
	<keyword>Interferon-beta</keyword>
</DOC>